|
|
|
09188
|
|
|
P.I.:
|
Robert Morgan, MD
|
(NCI Approved External Peer Review)
|
|
Title:
|
PHII-94/NCI#8351; A Multi-Histology Phase II Study of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine (FdCyd+THU)
|
| | |
|
|
09172
|
|
|
P.I.:
|
Robert Morgan, MD
|
(Cooperative Group)
|
|
Title:
|
GOG-0252: A Phase III Clinical Trial of Bevacizumab with IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma NCI-Supplied Agent(S): Bevacizumab (NSC #704865, IND #7921)
|
| | |
|
|
09100
|
|
|
P.I.:
|
Robert Morgan, MD
|
(NCI Approved External Peer Review)
|
|
Title:
|
PHII-92, NCI#8233: A Phase II Trial of Temsirolimus and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer
|
| | |
|
|
09016
|
|
|
P.I.:
|
Robert Morgan, MD
|
(Cooperative Group)
|
|
Title:
|
GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination with Bevacizumab followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Peritoneal Primary and Fallopian Tube Cancer
|
| | |
|
|
08240
|
|
|
P.I.:
|
Robert Morgan, MD
|
(NCI Approved External Peer Review)
|
|
Title:
|
PHI-63 NCI #8282: A Phase I Study of Chronically-Dosed, Single Agent ABT-888 in patients with Either BRCA 1/2-Mutated Cancer: Platinum Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal Like Breast Cancer
|
| | |
|